Arcadia Biosciences held its Annual Meeting on September 10, 2026, where stockholders approved the 2026 Omnibus Equity Incentive Plan and authorized a reverse stock split with a ratio between 1-for-2 and 1-for-10 to be determined by the Board before June 30, 2027. The company also ratified the appointment of Ramirez Jimenez International CPAs as its independent auditor and approved the issuance of common stock upon exercise of Series A-1 Preferred Investment Options from a private placement closed on June 12, 2026. Gregory D. Waller was elected as a Class II director, and executive compensation received an advisory approval. Arcadia Biosciences operates in the agricultural biotechnology industry, developing crop traits to improve yield and sustainability.

On August 31, 2026, Arcadia Biosciences received a notification from Nasdaq that its stockholders' equity of $633,000 as of June 30, 2026, failed to meet the minimum requirement of $2,500,000 under Listing Rule 5550(b)(1). The company has until October 15, 2026, to submit a compliance plan and may request an extension of up to 180 days. Failure to regain compliance could result in delisting from the Nasdaq Capital Market. Arcadia Biosciences operates in the agricultural biotechnology industry, developing crop traits and technologies.

Arcadia Biosciences reported a net loss attributable to common stockholders of $6.3 million ($2.09 per share) for the second quarter ended June 30, 2026, compared to a $4.5 million loss in the prior year period. Second-quarter revenues were flat at $1.44 million, while operating expenses decreased by $17,000 due to lower SG&A costs offsetting the absence of prior-year contingent liability gains. The company closed a $4 million private placement in June 2026, ending the quarter with $4.2 million in cash and using only $319,000 in operating cash flow. Zola sales exceeded $740,000 in July, signaling recovery from previous inventory constraints. Arcadia Biosciences is a producer and marketer of innovative wellness products and agricultural ingredients.

Arcadia Biosciences received a notice from Nasdaq on August 4, 2026, indicating non-compliance with the minimum bid price requirement due to its stock trading below $1.00 for 30 consecutive business days ending August 3, 2026. The company has an initial compliance period of 180 calendar days, until February 1, 2027, to restore the closing bid price to at least $1.00 for ten consecutive business days. Failure to comply may result in a second compliance period or delisting proceedings, with potential remedies including a reverse stock split. Arcadia Biosciences operates in the agricultural biotechnology industry, developing crop protection products and traits.

On July 1, 2026, the Board of Directors approved a discretionary cash bonus of $169,000 for CEO and Interim CFO Thomas J. Schaefer for the 2025 fiscal year. No other named executive officers received bonuses for 2025. Additionally, the company scheduled its 2026 annual meeting of stockholders for September 10, 2026, setting the deadline for director nominations and stockholder proposals as July 13, 2026. Arcadia Biosciences is an agricultural biotechnology company that develops seed technologies and plant-based proteins.

Arcadia Biosciences, Inc. entered into a securities purchase agreement on June 11, 2026, for a private placement of pre-funded warrants and investment options to an institutional investor for approximately $4 million in gross proceeds. The offering includes pre-funded warrants for up to 3,883,496 shares, Series A-1 and Series A-2 preferred investment options for an additional 3,883,496 shares, all at a purchase price of $1.0299 per unit. Arcadia Biosciences, Inc. is a biotechnology company focused on plant-based science and plant-based products.